IRONWOOD PHARMACEUTICALS INC 8K

Ironwood Pharmaceuticals raised its 2026 financial guidance following strong Q2 2026 LINZESS performance, repaid $200 million of convertible notes, advanced its Phase 3 apraglutide program, and announced key leadership changes.

Ironwood Pharmaceuticals, Inc. reported strong second quarter 2026 financial results highlighted by a 44% year-over-year increase in year-to-date U.S. LINZESS net sales to $555 million, total Q2 revenue of $113 million, GAAP net income of $51 million, and adjusted EBITDA of $83 million, and, on the back of this performance and improved net pricing, raised its full-year 2026 guidance for U.S. LINZESS net sales to $1.15–$1.20 billion, total revenue to $460–$485 million, and adjusted EBITDA to more than $310 million while also repaying $200 million of convertible notes with cash on hand, advancing its apraglutide program through active recruitment in the confirmatory Phase 3 STARS-2 trial in short bowel syndrome with intestinal failure, and announcing finance and R&D leadership changes.

Filing Facts

CIK

1446847

Ticker

IRWD

Form

8K

Source Type

fda

Accession

0001104659-26-091625

Alert Tier

7